Communicate with Supplier? Supplier
Bonnie Ms. Bonnie
What can I do for you?
Contact Supplier

HomeProductsNew Chemical MaterialsCandesartan Cilexetil Cas No 145040-37-5

Candesartan Cilexetil Cas No 145040-37-5

Payment Type:
L/C,T/T,D/P
Incoterm:
FOB,CFR,CIF,CPT,CIP
Min. Order:
1 Bag/Bags
Delivery Time:
10 Days
Transportation:
Ocean,Air
Port:
Shanghai,Beijing,Qingdao
Share:
  • Product Description
Overview
Product Attributes

BrandYFL

Supply Ability & Additional Informations

Packaging200L/PE Drum

Productivity2000MT/A

TransportationOcean,Air

Place of OriginShandong Prov.

Supply Ability2000MT/A

PortShanghai,Beijing,Qingdao

Payment TypeL/C,T/T,D/P

IncotermFOB,CFR,CIF,CPT,CIP

Delivery Time10 Days

Packaging & Delivery
Selling Units:
Bag/Bags
Package Type:
200L/PE Drum

[5-bromo-3 -[(1R)-(2, 6-dichloro-3-fluorophenyl) ethoxy] pyridine-2-yl] amine is an intermediate of Crizotinib, and Crizotinib is a multi-target protein kinase inhibitor developed by Pfizer to inhibit ATP of MET /ALK/ROS.

The clinical efficacy of crizotinib in humans was demonstrated in tumor patients with abnormal ALK, ROS and Met kinase activity, respectively.

It went on sale in the US in 2011 to great fanfare.

The inventor, Dr. Ching-Rong Cui (USPatent 7858643), won the 38th National Inventors of the Year award.

Purpose [5 - bromine - 3 - [(1 r) - (2, 6 - dichloro - 3 - phenyl) ethoxy] pyridine - 2 - base] is a useful research chemicals.

The application of [5-bromo-3 -[(1R)-(2, 6-dichloro-3-fluorophenyl) ethoxy] pyridine-2-yl] amine has been developed as an intermediate for crizotinib for the treatment of anaplastic lymphoma kinase (ALK) positive locally advanced and metastatic Chemicalbook non-small cell lung cancer (NSCLC).

The objective response rate for ALK-positive NSCLC patients treated with crizotinib was 60%, and progression-free survival was 8-10 months, which significantly improved and extended overall survival compared to chemotherapy.

Crizotinib intermediate [5-bromo-3 -[(1R)-(2, 6-dichloro-3-fluorophenyl) ethoxy] pyridine-2-yl] amine is the intermediate of Crizotinib, and Crizotinib (Crizotinib, Crizotinib) is a multi-target protein kinase inhibitor developed by Pfizer to inhibit ATP of MET /ALK/ROS.

The clinical efficacy of crizotinib in humans was demonstrated in tumor patients with abnormal ALK, ROS and Met kinase activity, respectively.

It went on sale in the US in 2011 to great fanfare.

The inventor, Dr. Ching-Rong Cui (USPatent 7858643), won the 38th National Inventors of the Year award.

[Indications] For the treatment of anaplastic lymphoma kinase (ALK) positive locally advanced and metastatic non-small cell lung cancer (NSCLC).

[Clinical Effectiveness] The objective response rate of crizotinib for ALK-positive NSCLC was 60%, and progression-free survival was 8-10 months, which significantly improved and extended overall survival compared to chemotherapy.

Looking for ideal Cas No 877399-00-3 Manufacturer & supplier ? We have a wide selection at great prices to help you get creative. All the High Quality 1-methylpiperazine are quality guaranteed. We are China Origin Factory of High Purity 99% 500011-92-7. If you have any question, please feel free to contact us.

Product Categories : New Chemical Materials

Email to this supplier
  • *To:
    Ms. Bonnie
  • *Message:
    Your message must be between 20-8000 characters
Bonnie

Ms. Bonnie

SEND INQUIRY

  • Tel:

    +86-531-88287585

  • Fax:

    86-531-88287585

  • E-mail:

    sales@yflchem.com

Home

Product

Phone

About Us

Inquiry